查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864579

Duchenne氏肌肉失養症治療藥物市場（依藥物類別、通路、最終用戶、劑型及給藥途徑分類）－2025-2032年全球預測

Duchenne Muscular Dystrophy Drugs Market by Drug Class, Distribution Channel, End User, Form, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Duchenne氏肌肉失養症治療市場將成長至 33.6 億美元，複合年成長率為 8.87%。

關鍵市場統計數據
基準年 2024 17億美元
預計年份：2025年 18.5億美元
預測年份 2032 33.6億美元
複合年成長率 (%) 8.87%

透過摘要整個生態系中的科學進展、臨床重點和相關人員的需求，為Duchenne氏肌肉失養症的治療策略奠定基礎。

Duchenne氏肌肉失養症仍然是臨床和商業性最複雜的罕見疾病領域之一，其特徵是進行性性肌肉退化、給看護者帶來沉重負擔，以及對疾病修正治療的持續需求。過去十年來的科學進步已將該領域從對症治療轉變為靶向分子干涉，從而構建了一個緊密交織的治療方法、監管合作和支付方參與策略的生態系統。臨床醫生、患者家屬和政策制定者越來越需要證據，不僅要證明生物活性，還要證明其具有實際的功能性療效、長期安全性以及永續的用藥模式。

在此背景下，產業相關人員面臨著一個需要整合藥物發現、臨床開發、生產和商業化等各環節的挑戰。新興治療方法，例如外顯子跳躍療法、基於腺相關病毒載體的基因替代療法以及改良型皮質類固醇療法，各自擁有獨特的科學原理、監管考慮和運作模式。此外，隨著精準醫療技術不斷改進病患選擇和療效評估方法，相關人員必須在創新與可擴展的生產和分銷模式之間取得平衡。本執行摘要整合了上述各方面內容，旨在為戰略決策提供背景資訊，並重點介紹加速產品研發管線轉化為患者獲益的潛在途徑。

前所未有的科學、製造和價值導向醫療保健轉型正在重塑Duchenne氏肌肉失養症治療的臨床開發、分銷和報銷策略。

過去幾年，Duchenne氏肌肉失養症的治療研發和實施方式發生了變革性變化，影響著臨床實驗設計、藥物生產和長期照護模式。科學創新使得針對該疾病潛在基因缺陷的標靶化更加精準，推動了治療模式從「一刀切」轉向針對特定治療方法的研發路徑，這需要個性化的監管和生產策略。同時，測量科學也日趨成熟，新型功能性終點、數位生物標記和患者報告結局被整合到關鍵研發項目中，以便在規模更小、更多樣化的人群中捕捉具有臨床意義的療效。

在營運層面，該產業正經歷同步的變革。依賴腺相關病毒（AAV）載體的基因療法正推動對載體生產能力、品管和長期安全監測系統的迫切投資。血清型選擇，例如AAV6或AAV9，會影響分佈動力學、組織親和性和生產複雜性，進而影響臨床策略和商業性可行性。同時，外顯子跳躍藥物和最佳化的皮質類固醇方案也在不斷改進，以在給藥、監測和目標患者群體方面展現差異化特性。這些技術和流程的變革正在促進生物技術公司、契約製造製造商和專科藥房之間的新合作，同時也促使支付方和醫療系統考慮採用基於績效的報銷和風險分擔模式，以應對高昂的前期成本和不確定的長期療效。

鑑於這些變化，行業領導者必須在研發早期整合科學、製造和商業計劃，以降低後期專案的風險，並協調相關人員對真實世界證據收集和患者獲取的期望。

評估計畫於 2025 年進行的美國關稅調整對Duchenne氏肌肉失養症治療藥物的供應鏈、製造地選擇和商業性准入策略的影響。

貿易政策變化和關稅考量已成為生物製藥供應鏈策略規劃的重要因素，而美國提案的2025年關稅調整方案，則為Duchenne氏肌肉失養症治療領域的企業帶來了新的變數。生物製藥生產的原料（例如質體DNA、特殊試劑、一次性使用系統和腺相關病毒（AAV）生產原料）在其生產週期中往往需要多次跨境運輸。因此，關稅和海關重新分類可能會增加到岸成本、延長前置作業時間，並促使獎勵重新評估供應商所在地。

為此，各組織正在重新評估其短期籌資策略，並尋求多元化以分散風險。一些公司正在加快對本地生產能力的投資，並簽訂長期供應協議，以確保價格可預測並優先分配產能。這些戰略選擇會產生連鎖反應。雖然回流或地域多角化可以降低進口關稅風險，但在嚴格的法規結構下對新的製造地進行認證可能需要大量的資金投入和時間。此外，不斷上漲的進口成本將影響與支付方和政府採購機構的價格談判，從而增加企業證明其臨床療效和成本效益的持續性壓力。

重點，跨境成本的上升將提升供應鏈透明度和庫存最佳化的重要性，促使企業實施更精細的需求預測、需求感知和緩衝庫存策略。監管和海關合規團隊應儘早參與計劃規劃階段，以避免因意外的商品分類變更而產生關稅。總而言之，雖然關稅只是眾多商業性變數之一，但其累積影響會影響生產策略、合作夥伴選擇以及將先進的Duchenne氏肌肉失養症療法引入不同市場的經濟效益。

將藥物類別、通路、終端用戶環境、劑型和給藥途徑整合到以細分市場主導的策略中，從而得出可操作的商業性和臨床結論。

從多個臨床和商業性角度考慮治療方法時，細分市場分析揭示了清晰的策略意義。依藥物類別分類，外顯子跳躍療法、基因療法和類固醇療法各自需要獨特的臨床開發模式和證據包。在基因療法領域，基於腺相關病毒（AAV）和非病毒療法之間的差異會影響載體選擇、免疫抗原性管理和生產路線決策。此外，深入研究血清型選擇，例如AAV血清型6或血清型9，決定了組織標靶化、給藥策略和生產規模的複雜性。考慮通路，可以發現醫院藥房、線上藥房和零售藥房之間存在不同的物流和合規要求。每種管道在低溫運輸、報銷和患者支援需求方面都面臨著獨特的挑戰。從最終使用者的觀點來看，居家醫療環境的需求與醫院或專科診所環境的需求有顯著差異，這會影響訓練、監測頻率以及輸液相關事件的緊急應變準備。劑型和給藥途徑對藥物的接受度和患者依從性至關重要，膠囊和口服片劑與注射劑或靜脈注射相比，能為患者帶來不同的用藥體驗。此外，肌肉注射、靜脈注射和口服給藥途徑各自都有其獨特的臨床監測和給藥基礎設施需求。

整合這些細分維度表明，產品組合設計不能孤立地進行。例如，用於醫院靜脈注射的基於AAV9的基因替代藥物候選產品的商業化投資，與透過零售藥局分銷供家庭使用的口服類固醇療法的商業化投資截然不同。因此，上市計劃必須從研發初期就將臨床設計與下游分銷、支付方參與和病患支援服務結合。這種整合觀點能夠提供反映實際應用情況的客製化價值提案，從而降低准入門檻，並為監管機構和支付方提供強力的證據支持。

評估美洲、歐洲、中東和非洲以及亞太地區在監管、報銷和營運方面的區域差異，以幫助制定分階段的市場進入和准入策略。

區域趨勢正在影響Duchenne氏肌肉失養症治療藥物的採納和准入途徑，每個地區都有其獨特的監管、報銷和運作方面的考慮。美洲擁有成熟的專科治療中心網路、完善的罕見疾病臨床試驗基礎設施，以及重視衛生技術評估和基於價值的合約的支付方，這些因素共同影響著藥物的核准順序和商業性化上市。在歐洲、中東和非洲地區，監管途徑各不相同，報銷決策往往涉及各國監管機構，而他們對療效比較證據的要求也存在差異，因此需要儘早協調不同的證據策略和建立區域特定的衛生經濟學模型。亞太地區擁有快速發展的臨床研究能力、日益成長的產業夥伴關係意願以及多元化的製造生態系統。然而，市場進入策略必須考慮到不同的監管要求、價格控制和患者准入計劃。

因此，區域策略應優先考慮靈活的監管路徑、分階段的市場准入計劃以及能夠充分利用當地臨床專長和分銷網路的夥伴關係。跨境物流規劃對於需要低溫運輸或即時給藥的先進醫療技術尤其重要，而區域製造地有助於患者儘早獲得治療，同時降低關稅和進口風險。最終，了解這些區域差異將有助於與相關人員進行更精準的合作，並透過使產品交付模式與當地醫療服務體系相契合，提高早期推廣應用的可能性。

分析企業在載體設計、生產規模化和相關人員參與方面的策略將如何決定Duchenne氏肌肉失養症治療藥物的臨床開發進展和商業化準備。

公司層面的趨勢對Duchenne氏肌肉失養症療法的創新速度和方向起著至關重要的作用。專注於外顯子跳躍和小分子療法的生物技術公司不斷改進有效載荷化學、遞送最佳化和患者選擇標準，以實現臨床差異化。致力於基因替代療法的機構則專注於載體設計、血清型選擇和可擴展的GMP生產，以減少批次間差異並支持穩定的臨床供應。在整個產業中，策略聯盟，例如研究合作、授權協議和生產夥伴關係，經常被用於彌補產能缺口並加快臨床試驗進程。

投資者和公司的優先事項也在轉變。除了臨床里程碑之外，營運執行、後期安全性監測計畫和商業化準備也日益受到重視。擁有整合臨床開發、生產規模化和與支付方合作策略的公司往往能更有效地應對後期關鍵節點。此外，病患權益組織和臨床醫師網路發揮強大的協調作用，影響臨床實驗試驗的招募、終點選擇和核准後證據的產生。因此，投資於透明的相關人員參與和患者支持基礎設施的公司可以提高臨床實驗參與率和長期應用率。最後，積極應對生產能力、供應鏈韌性和監管路徑的組織更有能力將研發成果轉化為患者可獲得的治療方法。

應採取綜合方法，將早期生產規劃、適應性證據產生、供應多樣化和以患者為中心的服務聯繫起來，以降低開發風險並加快獲取途徑。

行業領導者應採取協調一致、風險平衡的方法，將科學策略與生產和市場進入計劃相結合，以加速實現永續的患者獲益。首先，將生產的考量納入早期臨床設計決策，可降低後期供應受限的可能性，並有助於與監管機構就可比性和長期追蹤進行清晰的討論。其次，企業應優先考慮適應性證據的生成，將可靠的臨床終點與可操作的真實世界數據收集相結合，以支持產品迭代改進，同時滿足監管機構和支付方的需求。第三，供應商網路多元化和探索區域製造地可以降低關稅和跨境風險，而與經驗豐富的生物製藥生產商簽訂長期產能協議則可以確保關鍵原料的供應。

此外，以患者為中心的服務和數位化監測平台的投資將有助於提高患者依從性，獲取有意義的治療結果，並加強與支付方的價值評估。儘早與患者權益倡導組織進行透明的溝通，將加快患者招募速度，並使研發項目與對家庭至關重要的日常生活改善相契合。最後，領導者應尋求與研究機構、契約製造和專業分銷管道建立策略夥伴關係，以彌補產能缺口，並加快擴大患者群體的可及性。共同實施這些舉措，將建構一個更具韌性、以實證醫學為基礎的方法，為Duchenne氏肌肉失養症患者帶來變革性的治療方案。

請描述您的混合方法分析方法，該方法結合了專家訪談、監管審查和供應鏈映射，以檢驗策略見解，而無需依賴定量市場規模。

本執行摘要的研究採用了混合方法，旨在全面了解Duchenne氏肌肉失養症治療研發相關的科學、營運和商業性方面的問題。主要研究包括對臨床專家、生產專家、支付方顧問和患者權益組織代表進行結構化訪談，以檢驗治療方法的具體挑戰和證據預期。次要研究整合了同儕審查文獻、監管指導文件、臨床試驗註冊資訊和上市公司揭露資料，以梳理不斷發展的技術趨勢、安全性考量和試驗終點。交叉檢驗過程將訪談結果與文獻證據進行比較，以確保結果的一致性並減少偏差。

我們的分析方法著重於定性三角驗證和基於情境的風險評估，而非定量市場規模估算。我們特別關注生物製藥生產的供應鏈圖譜繪製，以及評估血清型選擇與基因療法臨床策略之間的相互作用。在適用情況下，我們參考監管先例和已發表的長期追蹤框架，並進行了上市後證據需求評估。本研究的限制包括臨床數據的流動性和政策環境的變化。因此，我們建議讀者結合新的試驗結果和監管決策來解讀我們的研究結果。

整合策略重點和營運挑戰，這將決定Duchenne氏肌肉失養症治療的科學進步能否轉化為持續的臨床益處和廣泛的患者群體。

總之，Duchenne氏肌肉失養症的治療格局正處於一個關鍵的轉折點，科學創新、生產現實和支付方的期望在此交匯，共同決定哪些治療方法能夠惠及患者以及這些療法在臨床實踐中的應用方式。外顯子跳躍、基因治療載體和最佳化類固醇療法的進展具有改變疾病進程的真正潛力，但要實現這一潛力，需要研發、生產和商業化團隊之間的協調規劃。對可擴展生產進行策略性投資、儘早與監管機構和支付方開展合作、制定全面的真實世界證據計劃以及建立健全的患者支持模式，將在將臨床潛力轉化為永續的患者可及性方面發揮關鍵作用。

在相關人員應對關稅政策、區域監管差異和不斷變化的證據標準之際，靈活性和積極的相關人員協作將使那些能夠迅速將科學突破轉化為永續的臨床和商業性成果的機構脫穎而出。未來的道路需要整合執行、與患者群體進行透明溝通，以及製定適應性強的證據策略，優先考慮可衡量的患者獲益，同時兼顧治療可及性的長期永續性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大以腺相關病毒載體（AAV）為基礎的Dystrophin基因治療在兒科患者的試驗
  • 加速針對第51號外顯子突變的CRISPR-Cas9基因組編輯計劃
  • 監管機構對Duchenne氏肌肉失養症藥物核准替代終點的接受度不斷提高
  • 生技公司與病患權益組織在臨床試驗設計上進行新的合作
  • 針對個體肌肉Dystrophin基因突變開發多外顯子跳躍療法
  • 人們對結合抗發炎藥物和肌肉再生藥物的聯合治療越來越感興趣。
  • 推出用於DMD試驗中功能性結果遠端監測的數位健康平台
  • 新一代腺相關病毒載體的進步提高了肌肉組織親和性和安全性。
  • 增加對幹細胞療法的投資，以恢復產生肌肉營養不良蛋白的肌肉細胞。
  • 隨著多國註冊機構的出現，有關 DMD 治療結果的真實世界證據正在被收集。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Duchenne氏肌肉失養症治療藥物市場（依藥物類別分類）

  • 外顯子跳躍
  • 基因治療
    • 基於AAV的
      • 血清型 6
      • 血清型 9
    • 非病毒性
  • 類固醇療法

第9章Duchenne氏肌肉失養症治療市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章Duchenne氏肌肉失養症治療市場（依最終用戶分類）

  • 家庭醫療保健環境
  • 醫院
  • 專科診所

第11章Duchenne氏肌肉失養症治療市場（按類型分類）

  • 膠囊
  • 注射
  • 口服錠劑

第12章Duchenne氏肌肉失養症治療藥物市場（依給藥途徑分類）

  • 肌肉內注射
  • 靜脈注射
  • 口服

第13章Duchenne氏肌肉失養症治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章Duchenne氏肌肉失養症治療市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國Duchenne氏肌肉失養症症治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Sarepta Therapeutics, Inc.
    • Pfizer Inc.
    • BioMarin Pharmaceutical Inc.
    • Roche Holding AG
    • Bayer Aktiengesellschaft
    • Solid Biosciences, Inc.
    • Cytokinetics, Inc.
    • NS Pharma, Inc.
Product Code: MRR-5E3B35529469

The Duchenne Muscular Dystrophy Drugs Market is projected to grow by USD 3.36 billion at a CAGR of 8.87% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.70 billion
Estimated Year [2025] USD 1.85 billion
Forecast Year [2032] USD 3.36 billion
CAGR (%) 8.87%

Setting the stage for Duchenne muscular dystrophy therapeutic strategies by summarizing scientific progress, clinical priorities, and stakeholder imperatives across the ecosystem

Duchenne muscular dystrophy remains one of the most clinically and commercially complex rare disease areas, characterized by progressive muscle degeneration, substantial caregiver burden, and a persistent need for disease-modifying therapies. Scientific advances over the past decade have shifted the field beyond symptomatic care toward targeted molecular interventions, creating a dense ecosystem of therapeutic modalities, regulatory interactions, and payer engagement strategies. Clinicians, families, and policymakers increasingly demand evidence not only of biological activity, but of meaningful functional benefit, long-term safety, and sustainable access models.

Against this backdrop, industry participants face a landscape that requires integrated thinking across discovery, clinical development, manufacturing, and commercialization. Emerging modalities such as exon skipping, gene replacement strategies using AAV vectors, and refined corticosteroid regimens each carry distinct scientific rationales, regulatory considerations, and operational footprints. Moreover, as precision medicine techniques refine patient selection and outcome measurement, stakeholders must balance innovation with scalable manufacturing and distribution approaches. This executive summary synthesizes those dimensions, providing context for strategic decisions and highlighting levers that can accelerate translation from pipeline to patient impact.

Unprecedented scientific, manufacturing, and value-based care shifts are reshaping clinical development, distribution, and reimbursement strategies for Duchenne therapeutics

The past several years have produced transformative shifts that are redefining how Duchenne therapies are developed and delivered, with consequences for trial design, manufacturing, and long-term care models. Scientific innovations have enabled more precise targeting of the genetic defects underpinning the disease, prompting a move away from one-size-fits-all approaches toward modality-specific development paths that require bespoke regulatory and manufacturing strategies. Concurrently, measurement science has matured: novel functional endpoints, digital biomarkers, and patient-reported outcomes are being integrated into pivotal development programs to capture clinically meaningful benefit in smaller, more heterogeneous populations.

Operationally, the industry is experiencing a parallel transition. Gene-based therapeutics reliant on AAV vectors are driving urgent investments in vector manufacturing capacity, quality control, and long-term safety monitoring systems. The choice of serotype, such as AAV6 or AAV9, now influences distribution kinetics, tissue tropism, and manufacturing complexity, which in turn affects clinical strategy and commercial viability. At the same time, exon skipping agents and optimized corticosteroid approaches continue to be refined, offering differentiated profiles in terms of administration, monitoring, and patient populations. These technological and procedural shifts are fostering new partnerships between biotech innovators, contract manufacturers, and specialty pharmacies, while also prompting payers and health systems to explore outcomes-based reimbursement and risk-sharing models to manage high upfront costs with uncertain long-term benefit trajectories.

Taken together, these shifts demand that industry leaders integrate scientific, manufacturing, and commercial planning earlier in development to de-risk late-stage programs and align stakeholder expectations around real-world evidence collection and patient access.

Assessing how anticipated United States tariff adjustments in 2025 may influence supply chains, manufacturing localization choices, and commercial access strategies for Duchenne therapies

Trade policy changes and tariff considerations have become material factors in strategic planning for biopharma supply chains, and proposed tariff adjustments in the United States during 2025 represent an additional variable for companies operating in the Duchenne therapeutic space. Raw materials for biologics production, including plasmid DNA, specialized reagents, single-use systems, and AAV manufacturing inputs, often cross borders multiple times during the manufacturing lifecycle. Consequently, tariffs or customs reclassifications can increase landed costs, extend lead times, and create incentives to re-evaluate supplier footprints.

In response, organizations are reassessing near-term sourcing strategies and exploring diversification to mitigate exposure. Some are accelerating investments in localized production capacity or entering long-term supply agreements to lock predictable pricing and prioritize capacity allocation. These strategic choices have knock-on effects: onshoring or regionalizing production can reduce exposure to import duties but may require significant capital expenditure and time to qualify new manufacturing sites under stringent regulatory frameworks. Moreover, increased import costs can influence pricing discussions with payers and government purchasers, intensifying pressure to demonstrate durable clinical benefit and cost-effectiveness.

Importantly, higher cross-border costs also elevate the value of supply chain transparency and inventory optimization, prompting firms to adopt more sophisticated forecasting, demand-sensing, and buffer stock policies. Regulatory and customs compliance teams will need to engage earlier in project planning to avoid unexpected classification changes that trigger tariffs. Overall, while tariffs are only one of many commercial variables, their cumulative impact can shape manufacturing strategies, partner selection, and the economics of bringing advanced Duchenne therapies to diverse markets.

Deriving practical commercial and clinical implications by integrating drug class, distribution channel, end-user context, form factors, and administration routes into segmentation-driven strategy

Segmentation analysis reveals distinct strategic implications when therapies are examined through multiple clinical and commercial lenses. When viewed by drug class, exon skipping agents, gene therapy approaches, and steroid regimens each demand unique clinical development paradigms and evidence packages; within gene therapy, the division between AAV-based and nonviral modalities affects vector selection, immunogenicity management, and manufacturing pathway decisions, while further consideration of AAV serotype choices such as serotype 6 and serotype 9 drives tissue targeting, dosing strategy, and production scale complexity. Examining distribution channels highlights the varying logistical and compliance requirements across hospital pharmacies, online pharmacies, and retail pharmacies, with each channel posing different cold-chain, reimbursement capture, and patient support needs. From an end-user perspective, the demands of home healthcare settings contrast sharply with hospital and specialty clinic environments, affecting training, monitoring cadence, and emergency preparedness for infusion-related events. Form and route of administration are central to adoption and patient adherence; capsules and oral tablets enable different patient journeys than injectables or intravenous administrations, and intramuscular, intravenous, and oral routes each carry specific clinical monitoring and administration infrastructure requirements.

Synthesizing these segmentation axes underscores that portfolio design cannot be siloed. For example, a gene replacement candidate using AAV9 intended for hospital-based intravenous administration will require different commercialization investments than an orally administered steroid therapy distributed through retail pharmacies for home use. Therefore, go-to-market planning must align clinical designs with downstream distribution, payer engagement, and patient-support services early in development. This integrated perspective enables tailored value propositions that reflect real-world use cases, reduce adoption friction, and support compelling evidence generation strategies for regulators and payers alike.

Evaluating regional regulatory, reimbursement, and operational nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform phased market entry and access strategies

Regional dynamics will shape the deployment and access pathways for Duchenne therapies, and each geography presents distinct regulatory, reimbursement, and operational considerations. In the Americas, there is a mature network of specialized centers, established rare disease clinical trial infrastructure, and payers that emphasize health technology assessment and value-based arrangements, which collectively influence the sequencing of approvals and commercial launches. In Europe, Middle East & Africa, regulatory pathways are diverse and reimbursement decision-making frequently involves national authorities with differing expectations for comparative effectiveness evidence, necessitating early alignment on heterogenous evidence strategies and localized health economic modeling. The Asia-Pacific region presents rapidly evolving clinical research capacity, a growing appetite for industry partnerships, and varied manufacturing ecosystems; however, market access strategies must account for divergent regulatory requirements, pricing controls, and patient access programs.

Consequently, regional strategies should prioritize flexible regulatory pathways, phased market entry plans, and partnerships that leverage local clinical expertise and distribution networks. Cross-border logistical planning is particularly important for advanced therapies with cold-chain or clinic-based administration needs, and regional manufacturing hubs can mitigate tariff or import vulnerabilities while supporting faster patient access. Ultimately, understanding these regional nuances enables more precise stakeholder engagement and increases the likelihood of early adoption by aligning product delivery models with local healthcare delivery architectures.

Analyzing how company strategies around vector engineering, manufacturing scale-up, and stakeholder engagement determine clinical progression and commercial readiness in Duchenne therapeutics

Company-level dynamics are pivotal in shaping the pace and direction of innovation in Duchenne therapeutics. Biotech firms focusing on exon skipping and small-molecule approaches continue to refine payload chemistry, delivery optimization, and patient-selection criteria to enhance clinical differentiation. Organizations pursuing gene replacement therapies are concentrating on vector engineering, serotype selection, and scalable GMP manufacturing to reduce batch-to-batch variability and support consistent clinical supply. Across the industry, strategic alliances-whether through research collaborations, licensing deals, or manufacturing partnerships-are frequently used to bridge capability gaps and accelerate time to clinic.

Investor and corporate priorities are also evolving: there is greater emphasis on operational execution, late-stage safety monitoring plans, and commercial readiness in parallel with clinical milestones. Companies with integrated strategies that align clinical development with manufacturing scale-up and payer engagement tend to navigate late-stage inflection points more effectively. In addition, patient advocacy groups and clinician networks are powerful conveners, influencing trial recruitment, endpoint selection, and post-approval evidence generation, so companies that invest in transparent stakeholder engagement and patient support infrastructure can strengthen both trial enrollment and long-term uptake. Finally, organizations that proactively address manufacturing capacity, supply chain resilience, and regulatory pathways are better positioned to translate R&D successes into accessible therapies for patients.

Adopt integrated actions linking early manufacturing planning, adaptive evidence generation, supply diversification, and patient-centered services to de-risk development and accelerate access

Industry leaders should adopt a coordinated, risk-balanced approach that links scientific strategy with manufacturing and market access planning to accelerate sustainable patient impact. Firstly, integrating manufacturing considerations into early clinical design decisions reduces the likelihood of late-stage supply constraints and enables clearer discussions with regulators about comparability and long-term follow-up. Secondly, firms should prioritize adaptive evidence generation that combines robust clinical endpoints with pragmatic real-world data collection to meet the needs of regulators and payers while supporting iterative product improvements. Thirdly, diversifying supplier networks and exploring regional manufacturing hubs can mitigate tariff and cross-border risks, while long-term capacity agreements with experienced biologics manufacturers can secure critical inputs.

Furthermore, investment in patient-centric services and digital monitoring platforms can improve adherence, capture meaningful outcomes, and strengthen value discussions with payers. Engaging patient advocacy groups early and transparently augments recruitment and aligns development programs with daily life improvements that matter to families. Lastly, leaders should pursue strategic partnerships-spanning research institutions, contract manufacturers, and specialty distribution channels-to fill capability gaps and accelerate time to broader access. Implementing these actions in concert will create a more resilient, evidence-driven approach to bringing transformative Duchenne therapies to patients.

Describe the mixed-methods analytical approach combining expert interviews, regulatory reviews, and supply chain mapping to validate strategic insights without relying on numerical market sizing

The research underpinning this executive synthesis utilized a mixed-methods approach to capture scientific, operational, and commercial dimensions relevant to Duchenne therapeutic development. Primary research included structured interviews with clinical experts, manufacturing specialists, payer advisors, and patient advocacy representatives to validate modality-specific challenges and evidence expectations. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly disclosed corporate filings to map technology trajectories, safety considerations, and trial endpoint evolution. Cross-validation steps compared insights from interviews with documentary evidence to ensure consistency and reduce bias.

Analytical methods emphasized qualitative triangulation and scenario-based risk assessment rather than quantitative market sizing. Special attention was given to supply chain mapping for biologics manufacturing and to evaluating the interplay between serotype selection and clinical strategy for gene therapies. Wherever applicable, regulatory precedent and published long-term follow-up frameworks informed the assessment of post-market evidence needs. Limitations include the evolving nature of clinical data and policy environments; consequently, readers are advised to consider these findings alongside emerging trial results and regulatory decisions as they become available.

Synthesize strategic priorities and execution imperatives that will determine whether scientific advances in Duchenne therapies translate into durable clinical benefit and broad patient access

In conclusion, the Duchenne therapeutic landscape is at a pivotal juncture where scientific innovation, manufacturing realities, and payer expectations converge to shape which therapies reach patients and how they are adopted in practice. Progress in exon skipping, gene therapy vectors, and optimized steroid regimens offers real potential to alter disease trajectories, but realizing that potential depends on synchronized planning across R&D, manufacturing, and commercial teams. Strategic investments in scalable manufacturing, early engagement with regulators and payers, comprehensive real-world evidence plans, and robust patient support models will be decisive in translating clinical promise into sustainable patient access.

As stakeholders navigate tariff policies, regional regulatory heterogeneity, and evolving evidence standards, flexibility and proactive stakeholder alignment will differentiate organizations that can rapidly convert scientific breakthroughs into durable clinical and commercial outcomes. The path forward requires integrated execution, transparent engagement with patient communities, and adaptive evidence strategies that prioritize measured benefit for patients while addressing the long-term sustainability of therapeutic access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of AAV-based micro-dystrophin gene therapy trials in pediatric patients
  • 5.2. Acceleration of CRISPR-Cas9 genome editing programs targeting exon 51 mutations
  • 5.3. Increasing regulatory acceptance of surrogate endpoints in Duchenne drug approvals
  • 5.4. Emerging collaboration between biotech innovators and patient advocacy groups for trial design
  • 5.5. Development of multiplex exon-skipping therapies customized to individual dystrophin gene mutations
  • 5.6. Growing focus on combination regimens integrating anti-inflammatory and muscle regeneration agents
  • 5.7. Adoption of digital health platforms for remote monitoring of functional outcomes in DMD trials
  • 5.8. Advancements in next-generation AAV vectors for enhanced muscle tissue tropism and safety
  • 5.9. Rising investments in stem cell therapy approaches to restore dystrophin-producing myocytes
  • 5.10. Emergence of multi-country registries capturing real-world evidence on DMD treatment outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Duchenne Muscular Dystrophy Drugs Market, by Drug Class

  • 8.1. Exon Skipping
  • 8.2. Gene Therapy
    • 8.2.1. Aav Based
      • 8.2.1.1. Serotype 6
      • 8.2.1.2. Serotype 9
    • 8.2.2. Nonviral
  • 8.3. Steroid Therapy

9. Duchenne Muscular Dystrophy Drugs Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Duchenne Muscular Dystrophy Drugs Market, by End User

  • 10.1. Home Healthcare Settings
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Duchenne Muscular Dystrophy Drugs Market, by Form

  • 11.1. Capsule
  • 11.2. Injectable
  • 11.3. Oral Tablet

12. Duchenne Muscular Dystrophy Drugs Market, by Route Of Administration

  • 12.1. Intramuscular
  • 12.2. Intravenous
  • 12.3. Oral

13. Duchenne Muscular Dystrophy Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Duchenne Muscular Dystrophy Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Duchenne Muscular Dystrophy Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Sarepta Therapeutics, Inc.
    • 16.3.2. Pfizer Inc.
    • 16.3.3. BioMarin Pharmaceutical Inc.
    • 16.3.4. Roche Holding AG
    • 16.3.5. Bayer Aktiengesellschaft
    • 16.3.6. Solid Biosciences, Inc.
    • 16.3.7. Cytokinetics, Inc.
    • 16.3.8. NS Pharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2024 (USD MILLION)
  • TABLE 288. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2025-2032 (USD MILLION)
  • TABLE 289. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2024